MVA-BN-Filo
AXP000201.1 · Vaccine
- Platform
- MVA-BN
- Targets
- Zaire ebolavirus GP; Sudan ebolavirus GP; Tai Forest ebolavirus NP; Marburg virus GP
- Originator
- Bavarian Nordic
- Sponsor
- Janssen-Cilag International
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA-BN
- Replication
- non replicating
- Modifications
- filovirus glycoprotein and nucleoprotein cassettes inserted into MVA-BN
- Transgenes
- Zaire ebolavirus GP (Mayinga), Sudan ebolavirus GP (Gulu), Tai Forest ebolavirus NP, Marburg virus GP (Musoke)
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| EMA | EU | 2020-07-01 | withdrawn | Mvabea | Active immunisation against Ebola virus disease (Zaire ebolavirus) from 1 year of age, as part of the Zabdeno/Mvabea regimen; authorised under exceptional circumstances and withdrawn 1 May 2026 at the holder's request | source |
Clinical trials (22)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06126822 | Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC | Recruiting | Phase 3 | 2025-02-25 | 2026-10 | 624 | Ebola Virus Disease |
| NCT05284097 | Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study | Completed | Phase 2 | 2022-09-19 | 2023-03-02 | 133 | Ebola; Filoviridae Infections; Hemorrhagic Fever, Ebola; Hemorrhagic Fevers, Viral; Immunologic Factors; Infections; Mononegavirales Infections; Physiological Effects of Drugs; RNA Virus Infections; Vaccines; Virus Diseases |
| NCT05064956 | Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) | Completed | Phase 2 | 2021-10-06 | 2021-11-17 | 26 | Ebola; Ebola Virus Disease; Hiv |
| NCT04711356 | Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) | Completed | Phase 2 | 2021-07-08 | 2021-09-17 | 50 | Ebola Virus Disease |
| NCT04556526 | A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women | Completed | Phase 3 | 2020-10-05 | 2023-03-02 | 4031 | Healthy |
| NCT04228783 | A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants | Completed | Phase 3 | 2020-02-18 | 2022-04-25 | 974 | Ebola |
| NCT04152486 | Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC | Unknown | Phase 3 | 2019-11-14 | 2022-01-31 | 20426 | Ebola Virus Disease |
| NCT03929757 | A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants | Completed | Phase 2 | 2019-08-19 | 2022-08-22 | 108 | Ebola Virus Disease |
| NCT04028349 | ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) | Completed | Phase 2 | 2019-08-01 | 2021-03-19 | 800 | Ebola Virus Disease |
| NCT02876328 | Partnership for Research on Ebola VACcinations | Completed | Phase 2 | 2017-03-27 | 2019-12-24 | 4789 | Ebola Virus Disease |
| NCT02860650 | A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults | Completed | Phase 1 | 2016-08 | 2017-05 | 72 | Healthy |
| NCT02661464 | Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo | Terminated | Phase 3 | 2016-05-31 | 2021-12-13 | 677 | Hemorrhagic Fever, Ebola |
| NCT02598388 | Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo | Completed | Phase 2 | 2015-12-10 | 2018-12-12 | 578 | Hemorrhagic Fever, Ebola |
| NCT02564523 | Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults | Completed | Phase 2 | 2015-11-06 | 2019-02-12 | 1075 | Hemorrhagic Fever, Ebola |
| NCT02509494 | Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo | Completed | Phase 3 | 2015-09-30 | 2019-06-28 | 1023 | Ebola Virus Disease |
| NCT02543567 | A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants | Completed | Phase 3 | 2015-09-21 | 2016-06-07 | 525 | Healthy |
| NCT02543268 | A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants | Completed | Phase 3 | 2015-09-21 | 2016-01-22 | 329 | Healthy |
| NCT02416453 | A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults | Completed | Phase 2 | 2015-06-15 | 2018-01-19 | 423 | Ebola Viral Disease |
| NCT02376400 | A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Completed | Phase 1 | 2015-04 | 2015-12 | 78 | Healthy |
| NCT02376426 | A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Completed | Phase 1 | 2015-03 | 2015-09 | 72 | Healthy |
| NCT02325050 | A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Completed | Phase 1 | 2015-01-08 | 2015-07-02 | 164 | Healthy |
| NCT02313077 | A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Completed | Phase 1 | 2014-12-17 | 2015-04-17 | 87 | Healthy |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41616038 | Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. | PLoS neglected tropical diseases | 2026 | cited by trial NCT02876328 |
| PMID 42061096 | A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines. | EBioMedicine | 2026 | name in abstract: MVA-BN-Filo |
| PMID 42326817 | Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease. | medRxiv : the preprint server for health sciences | 2026 | cited by trial NCT02876328 |
| PMID 39012798 | Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial. | The Journal of infectious diseases | 2025 | cited by trial NCT02416453 |
| PMID 39559990 | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial. | Emerging microbes & infections | 2025 | cited by trial NCT02876328 |
| PMID 40921806 | Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial. | Nature medicine | 2025 | cited by trial NCT04556526 |
| PMID 37673423 | Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. | The Journal of infectious diseases | 2024 | name in title: MVA-BN-Filo |
| PMID 37967326 | Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2024 | cited by trial NCT02876328 |
| PMID 38400193 | Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study. | Vaccines | 2024 | cited by trial NCT02661464 |
| PMID 38523332 | Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial. | Human vaccines & immunotherapeutics | 2024 | name in title: MVA-BN-Filo |
| PMID 38552653 | Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial. | The Lancet. Infectious diseases | 2024 | name in title: MVA-BN-Filo |
| PMID 38603720 | Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. | PLoS neglected tropical diseases | 2024 | cited by trial NCT02416453 |
| PMID 38657084 | Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2024 | cited by trial NCT02598388 |
| PMID 38793748 | Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial. | Vaccines | 2024 | cited by trial NCT02598388 |
| PMID 39040106 | Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination. | Frontiers in immunology | 2024 | name in abstract: MVA-BN-Filo |
| PMID 39227399 | Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases. | Nature communications | 2024 | cited by trial NCT02876328 |
| PMID 36273490 | Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. | The Lancet. Infectious diseases | 2023 | cited by trial NCT04711356 |
| PMID 37099841 | Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory. | EBioMedicine | 2023 | name in abstract: MVA-BN-Filo |
| PMID 37631885 | The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen. | Vaccines | 2023 | cited by trial NCT02509494 |
| PMID 37858585 | Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone. | The Lancet. Global health | 2023 | cited by trial NCT03929757 |
| PMID 37981473 | Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. | Vaccine | 2023 | cited by trial NCT05064956 |
| PMID 32939546 | Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. | The Journal of infectious diseases | 2022 | name in abstract: MVA-BN-Filo |
| PMID 34529962 | Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. | The Lancet. Infectious diseases | 2022 | cited by trial NCT02509494 |
| PMID 34529963 | Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. | The Lancet. Infectious diseases | 2022 | cited by trial NCT02509494 |
| PMID 35015777 | Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. | PLoS medicine | 2022 | cited by trial NCT02564523 |
| PMID 35260458 | Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. | BMJ open | 2022 | cited by trial NCT04152486 |
| PMID 35640636 | Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022 | name in title: MVA-BN-Filo |
| PMID 35725488 | Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. | Trials | 2022 | cited by trial NCT04556526 |
| PMID 36197845 | First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. | PloS one | 2022 | cited by trial NCT02860650 |
| PMID 36516078 | Randomized Trial of Vaccines for Zaire Ebola Virus Disease. | The New England journal of medicine | 2022 | cited by trial NCT02876328 |
| PMID 33217361 | Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. | The Lancet. Infectious diseases | 2021 | cited by trial NCT02416453 |
| PMID 33485369 | Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. | Trials | 2021 | cited by trial NCT02876328 |
| PMID 34588237 | Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. | BMJ open | 2021 | name in abstract: MVA-BN-Filo |
| PMID 34714820 | Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. | PLoS medicine | 2021 | cited by trial NCT02564523 |
| PMID 34930928 | Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. | NPJ vaccines | 2021 | cited by trial NCT02543268 |
| PMID 32315287 | Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. | The Journal of clinical investigation | 2020 | cited by trial NCT02313077 |
| PMID 33073737 | Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda. | Global health action | 2020 | name in title: MVA-BN-Filo |
| PMID 30796816 | Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. | The Journal of infectious diseases | 2019 | cited by trial NCT02376426 |
| PMID 30796818 | Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. | The Journal of infectious diseases | 2019 | cited by trial NCT02376400 |
| PMID 29895178 | EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country. | Clinical trials (London, England) | 2018 | cited by trial NCT02509494 |
| PMID 27925844 | A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. | Human vaccines & immunotherapeutics | 2017 | name in abstract: MVA-BN-Filo |
| PMID 26546548 | Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. | The Lancet. Infectious diseases | 2016 | name in title: MVA-BN-Filo |
| PMID 27092831 | Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. | JAMA | 2016 | cited by trial NCT02313077 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41176150 | Immunogenicity and safety of Ebola vaccines in children: A systematic review and meta-analysis. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2026 | name in abstract: MVA-BN-Filo |
| PMID 41519695 | Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease. | BMC infectious diseases | 2026 | name in abstract: Mvabea |
| PMID 42245043 | Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines. | medRxiv : the preprint server for health sciences | 2026 | name in abstract: MVA-BN-Filo |
| PMID 42506625 | Implementation of a Large-Scale Ebola Vaccination Campaign in Rwanda. | Vaccines | 2026 | name in abstract: MVA-BN-Filo |
| PMID 42941682 | Ebola Virus Disease in Pregnancy: Maternal-Fetal Outcomes, Vertical Transmission, and Implications for Vaccination-A Narrative Review. | Journal of clinical medicine | 2026 | name in abstract: MVA-BN-Filo |
| PMID 39932900 | Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data. | PLoS medicine | 2025 | name in abstract: MVA-BN-Filo |
| PMID 40173257 | Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses. | Science translational medicine | 2025 | name in abstract: MVA-BN-Filo |
| PMID 40337393 | Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development. | Annals of medicine and surgery (2012) | 2025 | name in abstract: MVA-BN-Filo |
| PMID 40634393 | Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine. | Nature communications | 2025 | name in abstract: MVA-BN-Filo |
| PMID 40934735 | Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. | Vaccine | 2025 | name in abstract: MVA-BN-Filo |
| PMID 37722397 | Prevention and post-exposure management of occupational exposure to Ebola virus. | The Lancet. Infectious diseases | 2024 | name in abstract: MVA-BN-Filo |
| PMID 38410448 | A Single-shot ChAd3 Vaccine Provides Protection from Intramuscular and Aerosol Sudan Virus Exposure. | bioRxiv : the preprint server for biology | 2024 | name in abstract: Mvabea |
| PMID 38526137 | Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions1. | Emerging infectious diseases | 2024 | name in abstract: MVA-BN-Filo |
| PMID 38662631 | Use of Ebola Vaccines - Worldwide, 2021-2023. | MMWR. Morbidity and mortality weekly report | 2024 | name in abstract: MVA-BN-Filo |
| PMID 39203952 | Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo. | Vaccines | 2024 | name in abstract: MVA-BN-Filo |
| PMID 39203955 | Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo. | Vaccines | 2024 | name in title: MVA-BN-Filo |
| PMID 39715748 | A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. | NPJ vaccines | 2024 | name in abstract: MVA-BN-Filo |
| PMID 35776140 | Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign. | The Journal of infectious diseases | 2023 | name in title: MVA-BN-Filo |
| PMID 37691146 | Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo. | Cell reports | 2023 | name in title: MVA-BN-Filo |
| PMID 37727795 | Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. | Frontiers in immunology | 2023 | name in abstract: MVA-BN-Filo |
| PMID 37940656 | Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. | NPJ vaccines | 2023 | name in title: MVA-BN-Filo |
| PMID 36016151 | Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. | Vaccines | 2022 | name in abstract: MVA-BN-Filo |
| PMID 36450746 | Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. | NPJ vaccines | 2022 | name in title: MVA-BN-Filo |
| PMID 33077299 | The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. | Vaccine | 2021 | name in abstract: MVA-BN-Filo |
| PMID 33514756 | Durable natural killer cell responses after heterologous two-dose Ebola vaccination. | NPJ vaccines | 2021 | name in abstract: MVA-BN-Filo |
| PMID 33676782 | Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. | Vaccine | 2021 | name in abstract: MVA-BN-Filo |
| PMID 33873076 | Ebola virus disease: current vaccine solutions. | Current opinion in immunology | 2021 | name in abstract: MVA-BN-Filo |
| PMID 34077301 | Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in Rwanda. | Human vaccines & immunotherapeutics | 2021 | name in abstract: MVA-BN-Filo |
| PMID 33335092 | Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. | NPJ vaccines | 2020 | name in abstract: MVA-BN-Filo |
| PMID 31243126 | Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. | Journal of virology | 2019 | name in abstract: MVA-BN-Filo |
| PMID 31909070 | Recurrent Ebolavirus disease in the Democratic Republic of Congo: update and challenges. | AIMS public health | 2019 | name in abstract: MVA-BN-Filo |
| PMID 29870747 | Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | 2018 | name in title: MVA-BN-Filo |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R56AI192635 | Evaluation of a pan-Filovirus virus-like particle (VLP) vaccine. | CINCINNATI CHILDRENS HOSP MED CTR | SINGH, KARNAIL | 2026–2026 | name in abstract: MVA-BN-Filo |
| ZIAAI000936 | Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | LANE, CLIFFORD | 2025–2025 | name in abstract: MVA-BN-Filo |
| P51RR013986 | IMMUNOGENICITY AND EFFICACY OF MVA-BN-FILO IN AN EBOLA AND A MARBURG MODEL | TEXAS BIOMEDICAL RESEARCH INSTITUTE | CARRION, RICARDO | 2011–2011 | name in title: MVA-BN-Filo |
Notes
Mvabea: MVA-BN encoding Zaire ebolavirus (Mayinga) GP, Sudan ebolavirus (Gulu) GP, Tai Forest ebolavirus nucleoprotein and Marburg virus (Musoke) GP; the boost of the two-dose Zabdeno (Ad26.ZEBOV) / Mvabea regimen. EU marketing authorisation 1 July 2020 under exceptional circumstances; withdrawn 1 May 2026 at the holder's request. Route (intramuscular) not stated on the EPAR page opened, so left empty.
How to cite
MVA-BN-Filo (AXP000201.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000201.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.